NZ721620B2 - Pharmaceutical preparation containing pyridylaminoacetic acid compound - Google Patents
Pharmaceutical preparation containing pyridylaminoacetic acid compound Download PDFInfo
- Publication number
- NZ721620B2 NZ721620B2 NZ721620A NZ72162015A NZ721620B2 NZ 721620 B2 NZ721620 B2 NZ 721620B2 NZ 721620 A NZ721620 A NZ 721620A NZ 72162015 A NZ72162015 A NZ 72162015A NZ 721620 B2 NZ721620 B2 NZ 721620B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- pharmaceutical preparation
- pyridin
- intraocular pressure
- ocular hypertension
- preparation containing
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract description 11
- 239000000825 pharmaceutical preparation Substances 0.000 title abstract description 6
- 239000002253 acid Substances 0.000 title description 5
- 206010030043 Ocular hypertension Diseases 0.000 abstract description 6
- 208000010412 Glaucoma Diseases 0.000 abstract description 5
- -1 (6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-yl amino) isopropyl Chemical group 0.000 abstract description 4
- 239000003795 chemical substances by application Substances 0.000 abstract description 4
- 150000003839 salts Chemical class 0.000 abstract description 4
- 239000011780 sodium chloride Substances 0.000 abstract description 4
- 230000000694 effects Effects 0.000 abstract description 3
- 230000004410 intraocular pressure Effects 0.000 abstract description 3
- 229940011051 isopropyl acetate Drugs 0.000 abstract description 3
- 230000001225 therapeutic Effects 0.000 abstract 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Chemical class CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 abstract 1
- 102220240796 rs553605556 Human genes 0.000 description 2
- LSIXBBPOJBJQHN-UHFFFAOYSA-N Santene Chemical compound C1CC2C(C)=C(C)C1C2 LSIXBBPOJBJQHN-UHFFFAOYSA-N 0.000 description 1
- JIEXZSFMUWGAJW-UHFFFAOYSA-N propan-2-yl 2-[[6-[2-(4-pyrazol-1-ylphenyl)-1-(pyridin-3-ylsulfonylamino)ethyl]pyridin-2-yl]amino]acetate Chemical compound CC(C)OC(=O)CNC1=CC=CC(C(CC=2C=CC(=CC=2)N2N=CC=C2)NS(=O)(=O)C=2C=NC=CC=2)=N1 JIEXZSFMUWGAJW-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- Y10S514/913—
Abstract
The purpose of the present invention is to discover which compounds among the vast number of pyridylamino acetic acid compounds exhibit a markedly superior intraocular pressure-lowering action and can serve as an intraocular pressure-lowering agent or as a therapeutic or prophylactic agent against glaucoma or ocular hypertension, and to discover the manner of administration and/or dosage at which the discovered compounds will impart an effective therapeutic or prophylactic effect when administered to patients (primarily humans).?Provided is a pharmaceutical preparation for lowering intraocular pressure or for preventing or treating glaucoma or ocular hypertension, said pharmaceutical preparation containing 0.0003-0.01% (w/v) of (6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-yl amino) isopropyl acetate or a salt thereof. laucoma or ocular hypertension, and to discover the manner of administration and/or dosage at which the discovered compounds will impart an effective therapeutic or prophylactic effect when administered to patients (primarily humans).?Provided is a pharmaceutical preparation for lowering intraocular pressure or for preventing or treating glaucoma or ocular hypertension, said pharmaceutical preparation containing 0.0003-0.01% (w/v) of (6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-yl amino) isopropyl acetate or a salt thereof.
Description
(12) Granted patent caon (19) NZ (11) 721620 (13) B2
(47) Publicaon date: 2021.12.24
(54) Pharmaceucal preparaon containing pyridylaminoacec acid compound
(51) Internaonal Patent Classificaon(s):
A61K 31/444 A61P 27/02 A61P 27/06
(22) Filing date: (73) Owner(s):
1.08 Santen Pharmaceutical Co., Ltd.
(23) Complete specificaon filing date: (74) Contact:
2015.01.08 n & Ferguson Pty Ltd
(30) Internaonal ty Data: (72) Inventor(s):
US 61/925,882 2014.01.10 SHAMS, Naveed
KROON, Henk-Andre
(86) Internaonal Applicaon No.: KAWATA Hisashi
KAWABATA Noriko
(87) Internaonal Publicaon number:
WO/2015/105144
(57) Abstract:
The purpose of the present invenon is to discover which compounds among the vast number
of pyridylamino acec acid compounds exhibit a markedly or cular pressurelowering
acon and can serve as an intraocular pressure-lowering agent or as a therapeuc
or prophylacc agent against glaucoma or ocular hypertension, and to discover the manner
of straon and/or dosage at which the discovered compounds will impart an effecve
therapeuc or prophylacc effect when administered to paents (primarily humans). Provided
is a ceucal preparaon for lowering intraocular pressure or for prevenng or treang
glaucoma or ocular hypertension, said pharmaceucal preparaon containing 0.0003-0.01% (w/
v) of (6-{[4-(pyrazolyl)benzyl](pyridinylsulfonyl)aminomethyl}pyridinyl amino) isopropyl
acetate or a salt thereof.
721620 B2
[Description]
[Title Of Invention] CEUTICAL PREPARATION CONTAINING
PYRIDYLAMINOACETIC ACID COMPOUND
[Technical Field]
The present invention relates to a pharmaceutical
preparation containing
isopropyl(6—{[4—(pyrazol—1—yl)benzyl](pyridin—3—ylsulfonyl)
aminomethyl}pyridin—2—ylamino)acetate or a salt thereof.
[Background Art]
Isopropyl
(6—{[4—(pyrazol—1—yl)benzyl](pyridin—3—ylsulfonyl)aminometh
yl}pyridin—2—ylamino) acetate is a compound represented by the
following formula (1), and is described as one of an enormous
number of pyridylaminoacetic acid compounds in Patent
ture 1.
n\/jLO/L\ 0)
(0-
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461925882P | 2014-01-10 | 2014-01-10 | |
| US61/925,882 | 2014-01-10 | ||
| PCT/JP2015/050366 WO2015105144A1 (en) | 2014-01-10 | 2015-01-08 | Pharmaceutical preparation including pyridylamino acetic acid compound |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NZ721620A NZ721620A (en) | 2021-08-27 |
| NZ721620B2 true NZ721620B2 (en) | 2021-11-30 |
Family
ID=
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12016501357A1 (en) | Pharmaceutical preparation containing pyridylamino acetic acid compound | |
| JP2016027060A5 (en) | ||
| KR100566701B1 (en) | Use of alpha-glucosidase inhibitors for treating high-risk impaired glucose tolerance | |
| DE60124730T2 (en) | NEW METHODS USING CHOLINESTERASEINHIBITORS | |
| RU2017127135A (en) | THERAPEUTICALLY AGAINST CANCER OF CANCER | |
| CN107223125B (en) | SGC stimulant | |
| CN109790167A (en) | SGC stimulant | |
| JP6749962B2 (en) | Inhibitor of reticulochoroidal disorder | |
| JP2010501511A (en) | Controlled release system and manufacturing method thereof | |
| JP2016540785A5 (en) | ||
| CN101466376A (en) | CCR5 antagonist for enhancing immune reconstitution and treating opportunistic infection in HIV patients | |
| CN108689942A (en) | Nitrogenous dicyclic compound and its preparation method and application | |
| JP2009513713A5 (en) | ||
| US11517571B2 (en) | Use of kinase inhibitors to manage tuberculosis and other infectious diseases | |
| AU2018302790A1 (en) | Compounds affecting pigment production and use thereof for treatment of bacterial diseases | |
| JPWO2010010702A1 (en) | Preventive or therapeutic agent for axial myopia | |
| CN111902140A (en) | Pharmaceutical composition for preventing or treating pruritus comprising HDAC6 inhibitor as active ingredient | |
| WO2005014572A8 (en) | Pyrimidylpyrrole derivatives active as kinase inhibitors | |
| WO2018160178A8 (en) | Pharmaceutically acceptable salts of b-guanidinopropionic acid with improved properties and uses thereof | |
| CN104173332B (en) | Application of ginkgolide compound | |
| JP2010531322A (en) | Synergistic combination of anthranilamidopyridine urea and benzamide derivatives | |
| JP2017523974A5 (en) | ||
| JP2022550221A (en) | Cognitive pharmacological treatment | |
| NZ721620B2 (en) | Pharmaceutical preparation containing pyridylaminoacetic acid compound | |
| CN110753540A (en) | Oral pharmaceutical formulation of regagliflozin |